Submit an Original Article

Will This Irritable Bowel Syndrome Drug Be a Cash Cow?: Synergy Pharmaceuticals Inc (SGYP)

From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 26, 2013 - 5:47am
As embarrassing and difficult to manage as chronic constipation and irritable bowel syndrome (IBS) are, there are surprisingly very few treatments available for patients at the moment. The treatments that do exist often cause diarrhea and nausea as side effects. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has been focusing on its lead investigational drug Plecanatide, which is aimed at treating chronic constipation and constipation predominant irritable bowel syndrome. Plecanatide is [...]

Continue reading this article »

Share This Article:

Submit an Original Article

Wall Street Buzz

MOST POPULAR